A large-scale multi-cohort study identified 23 plasma proteins associated with incident venous thromboembolism (VTE), 15 of which were previously unknown to the disease’s pathophysiology.
Key novel markers include TIMD4, TIMP4, Cystatin-C, and Transgelin, representing biological pathways such as extracellular matrix regulation, immunity, and vascular senescence.
Mendelian randomization (MR) provided significant evidence for a causal role of TIMD4 and suggestive evidence for TIMP4 and Cystatin-C in VTE risk.
The integration of aptamer-based (SomaScan) and antibody-based (Olink) proteomic platforms enhances the robustness of these findings across diverse populations.
